The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.
The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.
A user shared their 4-month progress using a serum with Minoxidil 10%, Progesterone, Azelaic acid, Retinoic acid, Latanoprost, and Hydrocortisone, along with PRP and Fotona laser treatments. They are pleased with the results and plan to continue with more PRP and laser sessions, without using Finasteride.
The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.
Adding RU58841 to a regimen of 2.5 mg dutasteride and 5 mg oral minoxidil for potential hair regrowth. Some users suggest a biopsy to determine the cause of hair loss, while others discuss the effectiveness and side effects of various treatments.
The user "Emotional_Fun4990" shared their progress after using 1mg Finasteride daily, 5% Minoxidil, and a 0.5mm Derma-roller twice a week for 2 months. They noticed additional hair growth below the hairline and on the neck. Other users provided positive comments and encouragement.
RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.
The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation is about the effectiveness of Redensyl for hair loss and whether to continue using Minoxidil alone, despite planning for a hair transplant eventually. The user also mentions using dermarolling, PRP therapy, and Nutrafol.
OP used oral Dutasteride and Minoxidil but saw significant improvement only after adding PRP treatments. PRP sessions every 4 months maintained the results, though it is expensive.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
Revivhair serum is discussed as a potential treatment for mild hair thinning, but skepticism exists about its effectiveness without proven treatments like finasteride, dutasteride, or minoxidil. Users share experiences with various treatments, noting side effects and exploring alternatives like topical dutasteride and alfatradiol.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
.
CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.
The user tried Redensyl but stopped using topical finasteride and continued with 5% minoxidil. They are experiencing hair loss and considering accepting baldness.
A 23-year-old male started using Redensyl and Aminexil, along with Tab BTN Ultra and Vitamin D3 supplements, for hair loss. He shared progress pictures after 45-50 days of treatment.
The individual has been using minoxidil for beard growth for over two years, started oral minoxidil and dutasteride six months ago, and began RU58841 three months ago, which significantly enhanced their results. They are open to answering questions about their hair loss treatment experience.
Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.
The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.